The T1D Fund: A Breakthrough T1D Venture
We are an innovative venture philanthropy fund that drives investments toward cures for type 1 diabetes.
A Fund unlike any other
The T1D Fund is one of the largest, most successful funds of its kind in the world and the only one focused on T1D.
In 2016, a group of volunteers identified the need to attract more private investment to drive the development of type 1 diabetes cures. Their vision resulted in the T1D Fund, an impact investment fund that has used a venture philanthropic approach to catalyze more than $900 million in investments in our mission and has transformed the life sciences market for T1D.
Through its investments in partnership with private capital, including venture capital, corporations, an foundations, the Fund seeks to attract the private investment necessary to advance cures for type 1 diabetes.
The Fund is going to be the key to finding a cure much more quickly.”
About the T1D Fund
Read more about the only venture philanthropy fund in the world focused on T1D.
We leverage philanthropic capital to build a portfolio of investments that are attractive to investors and are compelling to the T1D community.
Learn about our portfolio companies focused on improving lives, cell therapies, and disease-modifying therapies.
As a venture philanthropy fund, we approach investment opportunities slightly differently than either a venture capital fund or a non-profit organization.
Our Board of Directors, Investment Committee, and Partners and Advisors include experts in the financial and research fields.
The relationship between Breakthrough T1D and the T1D Fund
The T1D Fund is a wholly owned, not-for-profit subsidiary and the venture investment entity of Breakthrough T1D, the leading global organization focused on finding a cure for T1D and supporting those affected by it.
The Fund is governed by a distinct board and works in partnership with an independent Investment Committee. Led by a deeply experienced team of healthcare and investment professionals, the Fund leverages Breakthrough T1D’s extensive research, clinical, regulatory, and medical expertise and network to identify and support companies with the potential to accelerate the development of treatments and cures for T1D.
Through this unique relationship, the T1D Fund brings deep knowledge of the T1D ecosystem and industry dynamics to the broader life sciences investment community while helping portfolio companies advance and expedite the development of their clinical pipelines.
Together, the T1D Fund and Breakthrough T1D are united in their commitment to supporting innovation that accelerates progress toward cures.
